161 related articles for article (PubMed ID: 23615858)
1. Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.
Chan C; Cai Z; Reilly RM
Pharm Res; 2013 Aug; 30(8):1999-2009. PubMed ID: 23615858
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells.
Ngo Ndjock Mbong G; Lu Y; Chan C; Cai Z; Liu P; Boyle AJ; Winnik MA; Reilly RM
Mol Pharm; 2015 Jun; 12(6):1951-60. PubMed ID: 25919639
[TBL] [Abstract][Full Text] [Related]
3. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
4. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
5. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
Costantini DL; Villani DF; Vallis KA; Reilly RM
J Nucl Med; 2010 Mar; 51(3):477-83. PubMed ID: 20150272
[TBL] [Abstract][Full Text] [Related]
7.
Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
[TBL] [Abstract][Full Text] [Related]
8. Biotinylated polyacrylamide-based metal-chelating polymers and their influence on antigen recognition following conjugation to a trastuzumab Fab fragment.
Liu P; Boyle AJ; Lu Y; Reilly RM; Winnik MA
Biomacromolecules; 2012 Sep; 13(9):2831-42. PubMed ID: 22871127
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
Costantini DL; Bateman K; McLarty K; Vallis KA; Reilly RM
J Nucl Med; 2008 Sep; 49(9):1498-505. PubMed ID: 18703606
[TBL] [Abstract][Full Text] [Related]
10. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
Scollard DA; Chan C; Holloway CM; Reilly RM
Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
[TBL] [Abstract][Full Text] [Related]
11. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Cell Cytotoxicity and Comet Assay on HER2/neu Positive Cell Line Due to
Piroozfar B; Alirezapour B; Sedeh FM; Mirzaii M; Jalilian AR; Hashemizadeh M; Raisali G
Curr Radiopharm; 2022; 15(2):148-156. PubMed ID: 34182918
[TBL] [Abstract][Full Text] [Related]
13. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
[TBL] [Abstract][Full Text] [Related]
15. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
16. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM
Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy.
Aleanizy FS; Alqahtani FY; Seto S; Al Khalil N; Aleshaiwi L; Alghamdi M; Alquadeib B; Alkahtani H; Aldarwesh A; Alqahtani QH; Abdelhady HG; Alsarra I
Int J Nanomedicine; 2020; 15():5433-5443. PubMed ID: 32801698
[TBL] [Abstract][Full Text] [Related]
19. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
20. The effect of metal-chelating polymers (MCPs) for 111In complexed via the streptavidin-biotin system to trastuzumab Fab fragments on tumor and normal tissue distribution in mice.
Boyle AJ; Liu P; Lu Y; Weinrich D; Scollard DA; Ngo Njock Mbong G; Winnik MA; Reilly RM
Pharm Res; 2013 Jan; 30(1):104-16. PubMed ID: 22907419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
